Stocks · News reference

Goldman Sachs Maintains Buy on Praxis Precision Medicine, Raises Price Target to $575

Aug 21, 2026, 5:52 PMBenzinga Newsdesk

Goldman Sachs analyst Kevin Strang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $470 to $575.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Fiscal.aiOct 27, 2026, 10:01 PM
Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation
Praxis Precision Medicines, Inc. announced it will report its third quarter 2026 financial results on November 9, 2026, and will host an Investor Day on November 12, 2026.
PRAX
Fiscal.aiOct 22, 2026, 10:01 PM
Lennox-Gastaut Syndrome (LGS) Foundation Announces 2026 International LGS Awareness Day Partners
Praxis Precision Medicines is recognized as a 'Shine Sponsor' for the 2026 International LGS Awareness Day, supporting the foundation's mission to improve the lives of those affected by LGS.
PRAX
BenzingaOct 16, 2026, 1:37 PMBenzinga Newsdesk
JP Morgan Initiates Coverage On Praxis Precision Medicine with Overweight Rating, Announces Price Target of $700
PRAX
BenzingaOct 15, 2026, 10:25 AMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $1201 price target.
PRAX